Kevan L. Hartshorn, MD

Professor, Medicine

Kevan Hartshorn
617.638.5638
650 Albany St Evans Biomed Research Ctr

Biography

I am a Medical Oncologist Boston University Medical Center with principle focus on solid tumors. I am Director of the Hematology/Oncology Fellowship program at Boston University School of Medicine for 18 years and also on-site PI for multicenter clinical trials of chemotherapy and targeted agents for various cancers. I participates in cooperative clinical trials groups (NSABP, SWOG, Alliance, and AIDs Clinical Trials group) and to a lesser extent in industry related clinical trials. I did my clinical training in Internal Medicine at Boston City Hospital and then did Fellowship training in Hematology/Oncology at Massachusetts General Hospital. After this I joined the Attending staff at Boston City Hospital and feel very devoted to the mission of Boston Medical Center (the name of the Hospital formed by the merger of Boston City Hospital and Boston University Hospital). This mission is to provide, “Exceptional Care Without Exception”. Boston Medical Center is the main safety net hospital for the city of Boston and prides itself on providing cutting edge care to patient’s regardless or economic or social status. The hospital cares for a large population of African American and immigrant patients and has developed a number of special services (e.g. care navigators) to under-served patients get the care they need. In addition to the above clinical research interests, I have a particular interest in Geriatric Oncology and shared in developing a clinical Fellowship in Geriatric Oncology here which has now been in existence for about 10 years. I have a long standing interest in health care disparities as well. I have mentored numerous Fellows, Medical Students, Residents and College and High School students over the years in clinical care, clinical research and basic research.

In addition to my clinical interests have a laboratory research program related to innate immunology have had continuous NIH grant support for 30 years. Our research principally deals with innate immunity, which refers to immune responses that are hard-wired into the genome and provide a first line of protection against infection or transformed cells. Innate immune responses are sometimes also responsible for damaging inflammation. Defects or variants in innate immunity account for increased propensity for infections or harmful inflammation. As an example, people lacking one of the collectins found in blood are at greater risk for infection during neutropenia and have a greater risk for certain cancers. There is surprising complexity and specificity to innate immunity despite the fact that it provides protection even when a person has not been exposed to a specific infection. The main aspects of innate immunity we study include neutrophils and monocyte/macrophages, toll like receptors, and soluble immune defense proteins called collectins and defensins. We study how neutrophils and monocytes become activated in response to infectious organisms (viruses and bacteria), including studies of cell signaling, phagocytosis and oxidant production. We study how defensins and collectins kill bacteria or viruses and promote their uptake by neutrophils and monocytes. We have created or collaborate to create and test a variety of new recombinant versions of collectins and defensins, some of which have strongly increased antiviral or antibacterial activity. We also collaborate with members of the department of Biophysics in crystallographic studies of collectin structure in order to predict protein changes that might confer greater antimicrobial activity. We also collaborate in use of mouse models (e.g., mice in which collectin genes are deleted) to study the role of specific innate immune mediators in infection. A particular area of interest for us is the innate immune response to respiratory infection, especially influenza virus infection. Influenza virus and HIV (which we also study to some extent) are important examples of infections for which innate immunity is important since these viruses undergo continuous mutation thus evading adaptive immune responses (i.e., specific T and B cell responses).

Other Positions

  • Active Staff Privileges, Hematology & Medical Oncology, Medicine, Boston Medical Center
  • Member, BU-BMC Cancer Center, Boston University
  • Member, Pulmonary Center, Boston University
  • Graduate Faculty (Primary Mentor of Grad Students), Boston University School of Medicine, Graduate Medical Sciences

Education

  • Albert Einstein College of Medicine, MD
  • Williams College, MA
  • Williams College, BA

Publications

  • Published on 2/14/2020

    Parsons LM, An Y, Qi L, White MR, van der Woude R, Hartshorn KL, Taubenberger JK, de Vries RP, Cipollo JF. Influenza Virus Hemagglutinins H2, H5, H6, and H11 Are Not Targets of Pulmonary Surfactant Protein D: N-Glycan Subtypes in Host-Pathogen Interactions. J Virol. 2020 Feb 14; 94(5). PMID: 31826991.

    Read at: PubMed
  • Published on 12/13/2019

    Boehmer U, Potter J, Clark MA, Ozonoff A, Ceballos RM, Winter M, Hartshorn KL. Neighborhood Characteristics and Colorectal Cancer Survivors' Quality of Care. Health Equity. 2019; 3(1):619-627. PMID: 31872167.

    Read at: PubMed
  • Published on 10/22/2019

    van Eijk M, Hillaire MLB, Rimmelzwaan GF, Rynkiewicz MJ, White MR, Hartshorn KL, Hessing M, Koolmees PA, Tersteeg MH, van Es MH, Meijerhof T, Huckriede A, Haagsman HP. Enhanced Antiviral Activity of Human Surfactant Protein D by Site-Specific Engineering of the Carbohydrate Recognition Domain. Front Immunol. 2019; 10:2476. PMID: 31749796.

    Read at: PubMed
  • Published on 9/2/2019

    Keating M, Giscombe L, Tannous T, Hartshorn K. Prolonged Treatment Response to Pembrolizumab in a Patient with Pretreated Metastatic Colon Cancer and Lynch Syndrome. Case Rep Oncol Med. 2019; 2019:3847672. PMID: 31565451.

    Read at: PubMed
  • Published on 11/20/2018

    Sheikh AR, Yameen H, Hartshorn K. Treatment of Rectal Cancer in Older Adults. Curr Oncol Rep. 2018 11 20; 20(12):102. PMID: 30456634.

    Read at: PubMed
  • Published on 10/24/2018

    Elias R, Hartshorn K, Rahma O, Lin N, Snyder-Cappione JE. Aging,?immune senescence,?and immunotherapy:?A comprehensive review. Semin Oncol. 2018 08; 45(4):187-200. PMID: 30539714.

    Read at: PubMed
  • Published on 9/12/2018

    Shin TH, Inagaki E, Ganta T, Hartshorn K, Litle VR, Suzuki K. Tumor Lysis Syndrome After Bilobectomy for Typical Carcinoid Tumor of the Lung. Ann Thorac Surg. 2019 03; 107(3):e199-e201. PMID: 30218665.

    Read at: PubMed
  • Published on 7/17/2018

    Kumaradevan S, Lee SY, Richards S, Lyle C, Zhao Q, Tapan U, Jiangliu Y, Ghumman S, Walker J, Belghasem M, Arinze N, Kuhnen A, Weinberg J, Francis J, Hartshorn K, Kolachalama VB, Cifuentes D, Rahimi N, Chitalia VC. c-Cbl Expression Correlates with Human Colorectal Cancer Survival and Its Wnt/ß-Catenin Suppressor Function Is Regulated by Tyr371 Phosphorylation. Am J Pathol. 2018 08; 188(8):1921-1933. PMID: 30029779.

    Read at: PubMed
  • Published on 6/13/2018

    Hsieh IN, De Luna X, White MR, Hartshorn KL. The Role and Molecular Mechanism of Action of Surfactant Protein D in Innate Host Defense Against Influenza A Virus. Front Immunol. 2018; 9:1368. PMID: 29951070.

    Read at: PubMed
  • Published on 5/16/2018

    van Eijk M, Rynkiewicz MJ, Khatri K, Leymarie N, Zaia J, White MR, Hartshorn KL, Cafarella TR, van Die I, Hessing M, Seaton BA, Haagsman HP. Lectin-mediated binding and sialoglycans of porcine surfactant protein D synergistically neutralize influenza A virus. J Biol Chem. 2018 07 06; 293(27):10646-10662. PMID: 29769321.

    Read at: PubMed

View 159 more publications: View full profile at BUMC

View all profiles